Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alizyme PLC

Latest From Alizyme PLC

Deals Shaping The Medical Industry, February 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017

Deals BioPharmaceutical

Cetilistat approval puts Takeda first in Japan obesity market

The history of drug development for obesity in Japan is strewn with product casualties but Takeda has cleared a significant hurdle with the formal approval in this market of the lipase inhibitor Oblean (cetilistat).

Metabolic Disorders Japan

Cetilistat could become first obesity drug in Japan as Takeda files for approval

Takeda has filed for the approval in Japan of the lipase inhibitor cetilistat, seeking regulatory clearance for the treatment of obesity with complications including type 2 diabetes and dyslipidaemia.

Metabolic Disorders Cardiovascular

Stockwatch: They shoot biotech horses don't they?

This year, as well as last, the death of two horses at the recent UK Grand National race has led to a considerable amount of consternation amongst the horseracing, and even the general community. Interestingly, there are striking similarities between what has led to the death of so many UK biotechnology companies, and the changes that have led to the deaths at the Grand National.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Alizyme PLC
  • Senior Management
  • Timothy P McCarthy, CEO
    Neil Fish, PhD, Mgr., Bus. Dev.
    David Campbell , Dir., Fin.
  • Contact Info
  • Alizyme PLC
    Phone: (44) 1223 896000
    Granta Park
    Great Abington
    , CB1 6GX